Javier García Cogorro
Fondateur chez Columbus Venture Partners SGEIC SA
Profil
Javier García Cogorro is the founder of Columbus Venture Partners SGEIC SA, which was founded in 2015.
He is also the founder of Viralgen Vector Core SL.
Mr. García Cogorro's current job is as a Director at The National Alliance For Hispanic Health.
He is also a Director at Vivet Therapeutics SAS since 2017 and at Highlight Therapeutics SL.
His former jobs include being a Director at Asklepios BioPharmaceutical, Inc. and Artax Biopharma, Inc.Mr. García Cogorro's education includes an undergraduate degree from Universidad Complutense de Madrid and an MBA from Instituto Catolico de Administracion y Direccion de Empresas.
Postes actifs de Javier García Cogorro
| Sociétés | Poste | Début |
|---|---|---|
Columbus Venture Partners SGEIC SA
 Columbus Venture Partners SGEIC SA Investment ManagersFinance Columbus Venture Partners SGEIC SA (Columbus VP) is an independent Spanish venture capital firm which was founded in 2015 by Javier García Cogorro and Damià Tormo Carulla. The firm headquartered in Madri, Spain. | Fondateur | 01/01/2015 |
Vivet Therapeutics SAS
 Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Directeur/Membre du Conseil | 04/04/2017 |
The National Alliance For Hispanic Health
 The National Alliance For Hispanic Health Medical/Nursing ServicesHealth Services The National Alliance For Hispanic Health provides mental health services. The company was founded in 1973 and is headquartered in Washington, DC. | Directeur/Membre du Conseil | - |
Highlight Therapeutics SL
 Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Directeur/Membre du Conseil | - |
Viralgen Vector Core SL
 Viralgen Vector Core SL BiotechnologyHealth Technology Viralgen Vector Core SL is a contract development and manufacturing organization (CDMO) that produces AAV gene therapy treatments for pharmaceutical and biotech companies. The company was founded in 2017 by Javier García Cogorro and is based in Donostia-San Sebastian, Spain. Viralgen offers the Pro10™ based suspension manufacturing platform, which increases scalability, performance, and yield of AAV therapies. The Spanish company's clinical facilities have four CGMP manufacturing suites, with 250-liter and 500-liter bioreactors. In 2020, Viralgen expanded within the scientific park by constructing a new building for large-scale commercial manufacturing. The new state-of-the-art space includes three additional CGMP suites with a manufacturing capacity of >2,000 liters each, as well as a suite dedicated to fully automated fill and finish operations. The new facility has received the CGMP certification by the Spanish Agency for Medicines and Medical Devices (AEMPS) as part of the EMA network. The CEO is Jimmy Vanhove. | Fondateur | - |
Anciens postes connus de Javier García Cogorro
| Sociétés | Poste | Fin |
|---|---|---|
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Asklepios BioPharmaceutical, Inc.
 Asklepios BioPharmaceutical, Inc. BiotechnologyHealth Technology Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
Formation de Javier García Cogorro
| Universidad Complutense de Madrid | Undergraduate Degree |
| Instituto Catolico de Administracion y Direccion de Empresas | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Columbus Venture Partners SGEIC SA
Columbus Venture Partners SGEIC SA Investment ManagersFinance Columbus Venture Partners SGEIC SA (Columbus VP) is an independent Spanish venture capital firm which was founded in 2015 by Javier García Cogorro and Damià Tormo Carulla. The firm headquartered in Madri, Spain. | Finance |
Vivet Therapeutics SAS
Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Health Technology |
The National Alliance For Hispanic Health
The National Alliance For Hispanic Health Medical/Nursing ServicesHealth Services The National Alliance For Hispanic Health provides mental health services. The company was founded in 1973 and is headquartered in Washington, DC. | Health Services |
Asklepios BioPharmaceutical, Inc.
Asklepios BioPharmaceutical, Inc. BiotechnologyHealth Technology Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC. | Health Technology |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Highlight Therapeutics SL
Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Health Technology |
Viralgen Vector Core SL
Viralgen Vector Core SL BiotechnologyHealth Technology Viralgen Vector Core SL is a contract development and manufacturing organization (CDMO) that produces AAV gene therapy treatments for pharmaceutical and biotech companies. The company was founded in 2017 by Javier García Cogorro and is based in Donostia-San Sebastian, Spain. Viralgen offers the Pro10™ based suspension manufacturing platform, which increases scalability, performance, and yield of AAV therapies. The Spanish company's clinical facilities have four CGMP manufacturing suites, with 250-liter and 500-liter bioreactors. In 2020, Viralgen expanded within the scientific park by constructing a new building for large-scale commercial manufacturing. The new state-of-the-art space includes three additional CGMP suites with a manufacturing capacity of >2,000 liters each, as well as a suite dedicated to fully automated fill and finish operations. The new facility has received the CGMP certification by the Spanish Agency for Medicines and Medical Devices (AEMPS) as part of the EMA network. The CEO is Jimmy Vanhove. | Health Technology |
